Physician profile
Catherine Welch
NPI 1841079167
$4,216.85
in general payments reported to CMS, 2019-2025
24 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $415 · 2024: $2,359 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,216.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $775.30 | 2023-2025 | |
| Novo Nordisk INC | $500.94 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $496.52 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $469.80 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $384.63 | 2023-2025 | Veozah |
| Amgen INC. | $285.14 | 2024-2025 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $275.42 | 2023-2025 | |
| Pfizer INC. | $236.91 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $172.21 | 2023-2025 | Caplyta |
| Lundbeck LLC | $130.77 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $87.95 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $59.08 | 2023-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Esperion Therapeutics, INC. | $53.18 | 2023-2025 | Nexletol |
| Cycle Pharmaceuticals INC | $48.92 | 2025 | Sajazir |
| Glaxosmithkline, LLC. | $41.28 | 2024 | Arexvy, Trelegy Ellipta, Shingrix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $36.35 | 2024-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $24.24 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.31 | 2025 | Jardiance |
| Sanofi Pasteur INC. | $23.15 | 2025 | |
| Acadia Pharmaceuticals INC | $21.62 | 2025 | Nuplazid |
| Vanda Pharmaceuticals INC. | $20.35 | 2025 | Hetlioz, Fanapt |
| Exact Sciences Corporation | $19.45 | 2025 | The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $15.66 | 2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $14.67 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Welch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.